Inactive Instrument
Onconova Therapeutics Inc Share Price Nasdaq
Stocks
US68232V1089
Biotechnology & Medical Research
| Market Cap | 13.51M 11.82M 10.93M 10.2M 19.12M 1.28B 19.31M 130M 50.48M 628M 50.72M 49.62M 2.18B | P/E 2026 * |
-0.63x | P/E 2027 * | -0.7x |
|---|---|---|---|---|---|
| Enterprise Value | 13.51M 11.82M 10.93M 10.2M 19.12M 1.28B 19.31M 130M 50.48M 628M 50.72M 49.62M 2.18B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
90.56% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Onconova Therapeutics Inc
| 1 day | -5.13% |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Dukes
CEO | Chief Executive Officer | 67 | 30/03/2025 |
Charles Parker
DFI | Director of Finance/CFO | 46 | 04/07/2025 |
Robert Redfield
CTO | Chief Tech/Sci/R&D Officer | 74 | 31/03/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Jack Stover
CHM | Chairman | 73 | 14/04/2025 |
Mary Shoemaker
BRD | Director/Board Member | 64 | 31/03/2020 |
Trafford Clarke
BRD | Director/Board Member | 67 | 18/12/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -5.13% | +0.55% | - | - | 12.88M | ||
| +0.34% | +2.06% | -10.67% | -5.26% | 43.13B | ||
| +1.73% | +7.76% | +318.08% | +543.17% | 34.65B | ||
| +0.61% | +2.77% | +10.00% | +46.44% | 30.03B | ||
| +0.02% | -7.52% | +8.45% | -21.52% | 28B | ||
| -1.06% | -2.60% | +9.08% | +21.51% | 24.45B | ||
| -1.23% | +4.56% | - | - | 14.34B | ||
| -0.99% | -2.50% | +47.29% | +106.70% | 13.14B | ||
| +1.54% | -0.94% | +6.69% | +8.40% | 12.53B | ||
| +2.39% | +3.57% | +102.86% | +83.89% | 12.25B | ||
| Average | -0.18% | +0.65% | +61.47% | +97.92% | 23.61B | |
| Weighted average by Cap. | +0.40% | +1.19% | +67.04% | +113.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -21.3M -18.64M -17.23M -16.08M -30.15M -2.02B -30.44M -205M -79.58M -990M -79.96M -78.23M -3.44B | -24.25M -21.22M -19.61M -18.3M -34.32M -2.3B -34.66M -233M -90.61M -1.13B -91.04M -89.06M -3.92B |
| Net Debt | - | - |
Employees
-

















